Amneal Pharmaceuticals’ Q4 sales rose 18% to $730.52M, surpassing estimates, while adjusted EPS missed. The company forecasts up to $3.1B in 2025 revenue.
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars
More from STOCKMore posts in STOCK »
- Tech Shift Revives European Stocks This Week
- Binance data highlights Bitcoin price drop despite surge in spot buyer bids
- Tech giants lose $1 trillion as AI bubble fears spark sell-off
- What Does OpenAI’s $20 Billion Deal Mean for Nvidia’s Future Profits?
- Are You Missing Out on the Big ETF Inflows? Spot the Potential in SPY, AMZN, GOOGL, GOOG!
Comments are closed.